Nothing said here yet.
to join the conversation.
| Andersen JillChief Legal Officer, Secretary | Sell | 30,706 | $25.9K | Tue, Aug 18 |
| Lee Timothy EdwardChief Commercial Officer | Sell | 18,425 | $15.5K | Tue, Aug 18 |
| Duke William E.Chief Financial Officer | Sell | 18,425 | $15.5K | Tue, Aug 18 |
| Green JulieChief Human Resources Officer | Sell | 18,425 | $15.5K | Tue, Aug 18 |
| Allen Robert D. IIIChief Scientific Officer | Sell | 17,043 | $14.4K | Tue, Aug 18 |
| Andersen JillChief Legal Officer, Secretary | Sell | 37,256 | $26.9K | Mon, Aug 17 |
| Duke William E.Chief Financial Officer | Sell | 22,355 | $16.1K | Mon, Aug 17 |
| Lee Timothy EdwardChief Commercial Officer | Sell | 22,355 | $16.1K | Mon, Aug 17 |
| Green JulieChief Human Resources Officer | Sell | 22,355 | $16.1K | Mon, Aug 17 |
| Allen Robert D. IIIChief Scientific Officer | Sell | 20,679 | $14.9K | Mon, Aug 17 |
Invivyd (NASDAQ:IVVD) reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an accelerated-approval pathway with the U.S.…
Invivyd’s CEO said the biotech wants to move “as quickly as possible” to bring a new option for Covid protection in the US.
Invivyd reported statistically significant Phase 3 safety and tolerability results for VYD2311 compared with an mRNA-based COVID-19 vaccine and said it plans to pursue an Accelerated Approval BLA pending supportive results from its ongoing DECLARATION study.
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc.
NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as Chief Executive Officer (CEO) of the company.
Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of +6.67% and -13.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?